1. Home
  2. VIR vs PLSE Comparison

VIR vs PLSE Comparison

Compare VIR & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIR
  • PLSE
  • Stock Information
  • Founded
  • VIR 2016
  • PLSE 2014
  • Country
  • VIR United States
  • PLSE United States
  • Employees
  • VIR N/A
  • PLSE N/A
  • Industry
  • VIR Biotechnology: Pharmaceutical Preparations
  • PLSE Medical/Dental Instruments
  • Sector
  • VIR Health Care
  • PLSE Health Care
  • Exchange
  • VIR Nasdaq
  • PLSE Nasdaq
  • Market Cap
  • VIR 1.0B
  • PLSE 1.0B
  • IPO Year
  • VIR 2019
  • PLSE 2016
  • Fundamental
  • Price
  • VIR $9.83
  • PLSE $17.98
  • Analyst Decision
  • VIR Buy
  • PLSE
  • Analyst Count
  • VIR 5
  • PLSE 0
  • Target Price
  • VIR $36.40
  • PLSE N/A
  • AVG Volume (30 Days)
  • VIR 1.3M
  • PLSE 136.2K
  • Earning Date
  • VIR 10-31-2024
  • PLSE 10-30-2024
  • Dividend Yield
  • VIR N/A
  • PLSE N/A
  • EPS Growth
  • VIR N/A
  • PLSE N/A
  • EPS
  • VIR N/A
  • PLSE N/A
  • Revenue
  • VIR $78,618,000.00
  • PLSE N/A
  • Revenue This Year
  • VIR N/A
  • PLSE N/A
  • Revenue Next Year
  • VIR N/A
  • PLSE N/A
  • P/E Ratio
  • VIR N/A
  • PLSE N/A
  • Revenue Growth
  • VIR N/A
  • PLSE N/A
  • 52 Week Low
  • VIR $7.12
  • PLSE $4.57
  • 52 Week High
  • VIR $13.09
  • PLSE $22.69
  • Technical
  • Relative Strength Index (RSI)
  • VIR 80.05
  • PLSE 54.90
  • Support Level
  • VIR $7.12
  • PLSE $14.06
  • Resistance Level
  • VIR $10.44
  • PLSE $18.09
  • Average True Range (ATR)
  • VIR 0.51
  • PLSE 1.35
  • MACD
  • VIR 0.31
  • PLSE 0.07
  • Stochastic Oscillator
  • VIR 92.77
  • PLSE 89.91

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Share on Social Networks: